# ICER has called for increased transparency from the U.S. Food and Drug Administration (FDA) concerning its accelerated drug approval process.

*biotech · news · 2026-04-16 · Devdiscourse*

## Key points

- ICER is urging the FDA to provide more transparency on its accelerated drug approval process.
- FDA's use of surrogate endpoints in drug approvals is raising new reliability concerns.
- A study found tirzepatide causes more muscle loss than semaglutide in weight-loss treatment.
- OpenAI's GPT-Rosalind model was launched to enhance life sciences and biotechnology research.
- FDA may broaden testosterone therapy approval to men with idiopathic hypogonadism, not just known causes.

**Companies:** Eli Lilly, Novo Nordisk
**Countries:** United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3876935-transparency-in-drug-approvals-and-weight-loss-innovations-current-health-news-highlights)

---

Canonical: https://newsio.io/n/398d36f9-0230-4993-9dd4-81c4c1aa9a9e/icer-has-called-for-increased-transparency-from-the-u-s-food-and-drug-administra
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works